YAP1 and cancer: Finally, because YAP/TAZ and TEADs are discrete cancer dependencies that can be separated by lineage-specific determinants, and are not always unequivocally intertwined [30,53,54], the development of small molecule inhibitors specifically target either YAP or TEAD, possibly via proteolysis targeting chimera (PROTAC), would be a much-welcomed addition to the current therapeutic arsenal to attack these central transcriptional targets.